Ryan Scott's profile photo

Ryan Scott

Cranbury

Assistant Editor at OncLive

Assistant editor for @onclive. All tweets and thoughts are my own.

Featured in: Favicon onclive.com Favicon newsbreak.com Favicon cancernetwork.com Favicon contemporaryobgyn.net Favicon curetoday.com Favicon sailingworld.com Favicon targetedonc.com Favicon urologytimes.com Favicon oncnursingnews.com Favicon apparelviews.com

Articles

  • FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer

    2 months ago | curetoday.com | Ryan Scott

    The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type of brain cancer.

  • High PSA Levels Before HIFU May Increase Recurrence Risk in Intermediate-Risk Prostate Cancer

    Feb 15, 2025 | oncnursingnews.com | Ryan Scott

    Men with intermediate-risk prostate cancer and high prostate-specific antigen (PSA) levels before high-intensity focused ultrasound (HIFU) treatment faced a greater risk of recurrence and treatment failure, according to research presented at the 2025 ASCO Genitourinary Cancers Symposium. In this investigation of 108 men with intermediate-risk prostate cancer following HIFU, investigators found that in-field and overall recurrence on 1-year biopsy was 41% and 54%, respectively.

  • High PSA Before HIFU Tied to Increased Recurrence, Treatment Failure

    Feb 14, 2025 | targetedonc.com | Ryan Scott

    Research presented in a poster at the 2025 ASCO Genitourinary Cancers Symposium found that high prostate-specific antigen (PSA) levels before High-Intensity Focused Ultrasound (HIFU) were associated with a greater risk of overall recurrence and treatment failure in patients with intermediate-risk prostate cancer.

  • Oral Paclitaxel Outperforms IV in OS for Advanced Gastric Cancer

    Jan 28, 2025 | targetedonc.com | Ryan Scott

    Data from a phase 3 clinical trial (CTR20190050), presented at the 2025 Gastrointestinal Cancers Symposium, demonstrated that the oral solution of paclitaxel (Liporaxel) was non-inferior to the intravenous (IV) solution in progression-free survival (PFS) for second-line advanced gastric cancer. However, oral paclitaxel showed superior overall survival (OS) compared with the IV formulation.

  • Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST

    Jan 28, 2025 | onclive.com | Ryan Scott

    The combination of bezuclastinib (CGT9486) and sunitinib (Sutent) generated favorable efficacy outcomes compared with historical data, as well as long-term tolerability, in patients with previously treated gastrointestinal stromal tumors (GIST), according to findings from part 1 of the phase 3 Peak study (NCT05208047) that were presented at the 2025 Gastrointestinal Cancers Symposium.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
62
Tweets
22
DMs Open
No
Ryan Scott
Ryan Scott @ryanscottonc
11 Sep 24

In this episode of #OncLiveOnAir, Dr @garciamanero, of @MDAndersonNews, discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress. #MedEd #Hematology https://t.co/XYXKhrDdCr https://t.co/o1iqAvGnSo

Ryan Scott
Ryan Scott @ryanscottonc
3 Sep 24

Hear updates from the experts themselves on #OncLiveOnAir. This week, tune in to hear from Dr @DrRaviSalgia, of @cityofhope, as he shares how he chooses b/w tepotinib & capmatinib in pts w/ stage IV NSCLC harboring MET exon 14 skipping mutations. #lcsm https://t.co/pEXFbofrlN https://t.co/jtsBl9ngYh

Ryan Scott
Ryan Scott @ryanscottonc
29 Aug 24

❗ ICYMI: NXP800 was granted orphan drug designation by the @US_FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.💡 Read more from @OncLive here: https://t.co/7VFKAa08bp